User profiles for W. Denny

William A Denny

Distinguished Professor, The University of Auckland
Verified email at auckland.ac.nz
Cited by 42125

Prodrug strategies in cancer therapy

WA Denny - European journal of medicinal chemistry, 2001 - Elsevier
Systemic cytotoxic (anti-proliferative) anticancer drugs rely primarily for their therapeutic
effect on cytokinetic differences between cancer and normal cells. One approach aimed at …

Acridine derivatives as chemotherapeutic agents

WA Denny - Current Medicinal Chemistry, 2002 - ingentaconnect.com
Acridine derivatives are one of the oldest classes of bioactives, widely used as antibacterial
and antiprotozoal agents. Some work in these areas continues, but recent research has …

Genotoxicity of non-covalent interactions: DNA intercalators

LR Ferguson, WA Denny - Mutation Research/Fundamental and Molecular …, 2007 - Elsevier
This review provides an update on the mutagenicity of intercalating chemicals, as carried out
over the last 17 years. The most extensively studied DNA intercalating agents are acridine …

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

DW Fry, AJ Bridges, WA Denny… - Proceedings of the …, 1998 - National Acad Sciences
A class of high-affinity inhibitors is disclosed that selectively target and irreversibly inactivate
the epidermal growth factor receptor tyrosine kinase through specific, covalent modification …

Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality

…, DM Bouley, EE Graves, WA Denny… - Science translational …, 2011 - science.org
Identifying new targeted therapies that kill tumor cells while sparing normal tissue is a major
challenge of cancer research. Using a high-throughput chemical synthetic lethal screen, we …

Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of minimal DNA-intercalating agents which …

WA Denny, GW Rewcastle… - Journal of medicinal …, 1990 - ACS Publications
A series of substituted 2-phenylbenzimidazole-4-carboxamides has been synthesized and
evaluated for in vitro and in vivo antitumor activity. These compounds represent the logical …

Tyrosine kinase inhibitors. 8. An unusually steep structure− activity relationship for analogues of 4-(3-bromoanilino)-6, 7-dimethoxyquinazoline (PD 153035), a potent …

…, DW Fry, AJ Kraker, WA Denny - Journal of medicinal …, 1996 - ACS Publications
4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (32, PD 153035) is a very potent inhibitor (IC
50 0.025 nM) of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR), …

Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor:  4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d] …

…, PW Vincent, WL Elliott, WA Denny - Journal of medicinal …, 2000 - ACS Publications
4-Anilinoquinazoline- and 4-anilinopyrido[3,2-d]pyrimidine-6-acrylamides substituted with
solubilizing 7-alkylamine or 7-alkoxyamine side chains were prepared by reaction of the …

Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding

WB Denny, DL Valentine, PD Reynolds… - …, 2000 - academic.oup.com
Squirrel monkeys have high circulating cortisol to compensate for expression of low-affinity
glucocorticoid receptors (GRs). We have demonstrated that the FK506-binding immunophilin …

Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl) amino]-and 4-(phenylamino) quinazolines as potent adenosine 5' …

GW Rewcastle, WA Denny, AJ Bridges… - Journal of medicinal …, 1995 - ACS Publications
A series of 4-substituted quinazolines and related compounds have been prepared and
evaluated for their ability to inhibit the tyrosine kinase activity of the epidermal growth factor …